There is a concerted effort being put into refining and reforming the medical industry and Eric Lefkofsky, co-founder of Tempus, is helping to lead the way. Tempus is a data-driven firm that is focused on helping patients and medical professionals to compile data into an easy-to-access format so as to make cancer care more effective and efficient than ever. Tempus was established in 2015 and over the past three years, the company has managed to grow by leaps and bounds. With dramatic funding efforts underway, Tempus looks to be lined up to do big things in 2018 and beyond.
Tempus is a Chicago-based start-up that has been working within the tech industry and succeeding thanks to Lefkofsky’s unique ideas. Lefkofsky pioneered the creation of Tempus after seeing first-hand the harsh realities of cancer care in the current medical climate. Lefkofsky saw early on how important accurate and accessible information was for both medical professionals and patients currently working their way through a diagnosis.
Tempus currently rosters nearly 400 employees and their company is forecasting adding a dramatic amount of new workers to the roster on a continual basis going forward. Tempus is adding roughly 30 new employees per month and that pace is expected to continue going forward. With this continued expansion, Chicago is sitting pretty as the home of one of the most important new tech-based medical companies in the country.
Right now, Tempus is valued at roughly $1.1 billion according to their latest valuation. This valuation number allows Tempus to score the ‘Unicorn Status’ label that so few companies can ever actually claim. Tempus recently announced that they had received an additional $80 million in funding from a group of different investors, pushing their total investment numbers past $210 million since their inception in 2015. Among the new investors are clients like New Enterprise Associates, T. Rowe Price Associates, Kinship Trust Co and Revolution Growth.
Lefkofsky calls his work with Tempus more than just important, he claims that it is indicative of a ‘paradigm shift’ in the medical and technological field. With any luck, this will serve as just the beginning to a huge year for Tempus and cancer care patients everywhere.